wert WKN: A407ZR ISIN: NL0015001ZQ0 Kürzel: AFMD Forum: Aktien User: value3000

Fällt weiter wie ein Stein.

Von hier aus kann es nur noch aufwärts gehen. Und das tut es wohl auch..

Moin zusammen! Im alten Thread war ein Interview mit dem GF verlinkt, worin er erwähnte, noch für zwei Jahre Geld zu haben. Weiß jemand, wann das war und wie es aktuell aussieht?

Das weiß ich leider nicht mehr wann das war. Aber ich meine das war ein paar Monate vor dem RS. Also irgendwann in 2023

Affimed wird am 14. November 2024 die Finanzergebnisse und das Unternehmensupdate für das dritte Quartal 2024 bekannt geben.

Je besser die Daten, desto schlechter die Bewertung des Unternehmens.

https://seekingalpha.com/symbol/AFMD/comments

https://www.insidermonkey.com/blog/affimed-n-v-nasdaqafmd-upgraded-by-laidlaw-1314001/

Alle investierten sind hier auf dem besten Weg für ihre Geduld belohnt zu werden. Es werden weitere relevante readouts der laufenden Studien noch in 2024 kommen und - wie in dem obigen Artikel erwähnt - die Phantasie ist zurück! Mit einer hohen Volatilität muss aber dennoch gerechnet werden in nächster Zeit. Das bringen solche „good News“ bei entsprechend niedrigen Handelsvolumen halt mit sich (da machen manche auch schnelles Geld). Einfach investiert bleiben und in ein paar Jahren über heutige Kurse lachen 🙃

https://transkript.de/artikel/2024/hat-sich-bei-affimed-das-warten-gelohnt/

Aber egal, wie gut die Nachrichten sind, wird das Ding immer sofort wieder runtergeprügelt.

TOP! Acimtamig (AFM13) combination with AlloNK® (AB-101) natural killer (NK) cells: Recruitment in cohorts 1 and 2 completed. In the first 7 treatment refractory Hodgkin Lymphoma (HL) patients, an ORR of 85.7% observed, with 4 CRs and 2 partial responses (PRs) were observed by independent read. AFM24 combination with atezolizumab: In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1 treatment, 1CR, 3PRs and 8 SDs were observed. Disease control was 71%.

Positiv 👍🏻

Program Updates Acimtamig (AFM13; CD30 / CD16A) Independent read data from the first 7 patients show an ORR of 85.7 % with 4 CRs and 2 PRs. All patients were heavily pretreated with a median of 4 lines of prior treatment including combination chemotherapy, brentuximab vedotin and checkpoint inhibitors; 71 % (5/7 patients) had also failed after prior autologous stem cell transplantation (ASCT). Treatment related adverse events were consistent with previous experience and were mainly mild to moderate IRR/CRS in nearly two thirds of the patients (4/7). One patient developed a short-lasting grade 3 CRS but was also diagnosed to have acute cytomegalovirus infection. All side effects were well manageable with standard of care treatment and there were no treatment discontinuations due to acimtamig or AlloNK® related adverse events. No cases of bleeding, immune effector cell-associated neurotoxicity syndrome or graft-versus-host disease were observed. Enrollment in cohorts 1 and 2 is completed; cohorts 3 and 4 are now open and enrolling. Continued updates from the study to be provided on upcoming earnings calls and scientific conferences. AFM24 (EGFR / CD16A) In the AFM24-102 trial (combination with atezolizumab): 4 confirmed responses (1CR, 4PR) and 8SD in 17 heavily pretreated EGFRwt NSCLC patients; mPFS of 5.9 months; 3 out of 4 responses ongoing for more than 7 months. All patients were pretreated with platinum-based chemotherapy and checkpoint inhibitors PD [L]-1. On May 29, the Company announced that it received FDA Fast Track designation for the combination treatment of AFM24 with atezolizumab for EGFRwt NSCLC patients. In 13 response-evaluable, heavily pretreated EGFRmut NSCLC patients, the combination of AFM24 with atezolizumab showed encouraging signals of clinical activity, including 1 CR, 3 PRs and 6 SDs. All responses are ongoing and have been confirmed by follow up scan. ORR and PFS data from the 25 patient EGFRmut NSCL cohort is expected in Q3 2024; data from the 40 patient EGFRwt cohort is expected in Q4 2024. AFM28 (CD123 / CD16A) Completed enrollment of the sixth and final cohort in the multi-center Phase 1 open-label, dose-escalation study (AFM28-101), of AFM28 monotherapy in CD123-positive r/r acute myeloid leukemia (AML). Of 6 patients treated at dose level 6 at 300mg, 1 patient showed a CR, 1 patient a CRi and 3 patients achieved SD, a CR/CRi rate of 33%. Of 6 patients treated at dose level 5 at 250 mg, 1 patient showed a CR, ongoing after 5 months; 5 patients achieved a SD as best response. No dose-limiting toxicities were reported in dose levels 5 and 6. Data from the study is expected to be presented at a future scientific conference. Further clinical development of AFM28 to be pursued in combination with an allogeneic, off-the-shelf NK cell product. Upcoming Milestones: Data readout from the 12 patients in cohorts 1 and 2 of the LuminICE-203 (AFM13 combination with AlloNK® cells) study in Q3 2024. ORR and PFS data from the 25 patients in the EGFRmut cohort of the AFM24-102 study in Q3 2024. ORR and PFS data from the 40 patients in the EGFRwt cohort of the AFM24-102 study in Q4 2024.

Die 8 dollar sind ein harter brocken